cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 23, 2018 (NCT03326921)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia · Phase 1
- Leukemia, Biphenotypic, Acute · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Leukemia, Myelomonocytic, Juvenile · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasm, Residual · Phase 1
- Plasmacytoma · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03326921 | Phase 1 | Jun 23, 2018 | PromiCell Therapeutics, Inc., University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PromiCell Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2018 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1